基于骨髓样本的多发性骨髓瘤微小残留病检测中国专家共识(2024年版)  

Chinese expert consensus on minimal residual disease detection in multiple myeloma based on bone marrow samples (2024)

作　　者：中华医学会血液学分会实验诊断学组、浆细胞疾病学组 中国医师协会多发性骨髓瘤专业委员会 吴德沛[2] 黄晓军[3] 陈苏宁[4] 常英军[5] 傅琤琤[4] 路瑾[5] 朱明清[4] 姚利[4] Experimental Diagnostic Group,Plasma Cell Disease Group,Chinese Society of Hematology,Chinese Medical Association;Multiple Myeloma Professional Committee of Chinese Medical Doctor Association;Wu Depei;Huang Xiaojun(不详;National Clinical Research Center for Hematological Diseases,Jiangsu Institute of Hematology,First Affiliated Hospital of Soochow University,Suzhou 215006,China;National Clinical Research Center for Hematological Diseases,Peking University People's Hospital,Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematology,Beijing 100044,China)

机构地区：[1]不详 [2]国家血液系统疾病临床医学研究中心,江苏省血液研究所,苏州大学附属第一医院,苏州215006 [3]国家血液系统疾病临床医学研究中心,北京大学人民医院,北京大学血液病研究所,造血干细胞移植治疗血液病北京市重点实验室,北京100044 [4]苏州大学附属第一医院 [5]北京大学人民医院

出　　处：《中华血液学杂志》2024年第6期534-541,共8页Chinese Journal of Hematology

基　　金：国家重点研发计划(2022YFC2502700);国家自然科学基金(82020108003、82330008);江苏省血液病医学创新中心(CXZX202201)。

摘　　要：多发性骨髓瘤(MM)是血液系统第二大常见恶性肿瘤,标准的整体治疗模式及以新药为主的方案极大地改善了MM患者的生存,但微小残留病(MRD)导致大多数患者复发。因此,需要在传统血清学疗效评估的基础上联合MRD检测,以更精准地评估患者的疾病状态。目前,二代流式细胞术(NGF)和二代测序(NGS)是基于骨髓样本检测MRD的主流技术。为使MRD检测标准化和规范化,专家组讨论制订了在MM患者中应用NGF和NGS技术进行骨髓MRD检测的中国专家共识。Multiple myeloma(MM)is the second most common hematologic malignant tumor.Standard holistic treatment model and new drug-based regimens have greatly improved the survival of patients with MM;however,minimal residual disease(MRD)causes relapse in most patients.Therefore,combining MRD testing on the basis of traditional serological efficacy evaluation is necessary to achieve a more accurate assessment of the patient's disease status.At present,next-generation flow cytometry(NGF)and next-generation sequencing(NGS)are the mainstream technologies for detecting MRD based on bone marrow samples.To standardize and normalize MRD detection,the expert group discussed and formulated Chinese expert consensus on the application of NGF and NGS technology for bone marrow MRD detection in patients with MM.

关 键 词：多发性骨髓瘤 微小残留病 二代流式细胞术 二代测序 

分 类 号：R733.3[医药卫生—肿瘤]